-
FDA approves innovative oral therapy to prevent hereditary angioedema
Time of Update: 2021-03-08
“ FDA approved Orladeyo to fulfill BioCryst's commitment to HAE patients to help them develop an oral drug that will fulfill their dream of preventing and reducing the burden of disease seizures.
-
Stone Pharmaceutical Group "first-in-class" antibody new drug approved clinically
Time of Update: 2021-03-08
According to stone pharmaceutical group announcement, ALMB-0166 is a targeted half-channel membrane protein Connexin 43 "first-in-class" humanized monoclonal antibody inhibitor, developed by its subsidiary AlaMab Therapeutics (hereinafter referred to as "AlaMab"), to develop the treatment of acute spinal cord injury, stroke, osteoarthritis and other major neurological diseases.
-
$1 billion to develop innovative protein degradation therapies
Time of Update: 2021-03-08
yesterday, AbbVie and Frontier Pharmaceuticals jointly announced a global strategic partnership that will jointly identify, develop and commercialize innovative small-molecule drug pipelines for "non-essential" protein targets using Frontier's unique chemical proteomics technology platform.
-
The phase III drug study of Psoriasis in BMS met the standard
Time of Update: 2021-03-06
POETYK PSO-1 is the first of two global III studies to assess the safety and effectiveness of deucravacitinib in patients with moderate to severe plaque-like psoriasis compared to placebo and Otezla .
-
AstraZenecom's Dagrid Net DAPA-CKD III study
Time of Update: 2021-03-06
A new subgroup analysis of AstraZeneta's groundbreaking Dagley Net DAPA-CKD III clinical study shows that, on a standard basis, Dagrid Net can delay renal function deterioration and reduce the risk of cardiovascular or kidney disease death in patients with chronic kidney disease (CKD), regardless of the cause.
-
Sanofi's Sarclisa is recommended by NICE
Time of Update: 2021-03-06
The recommendation is based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex can reduce the risk of disease progress or death in adults by 40 percent.
-
AstraZeneia's heart failure drug Forxiga has been approved by the European Union
Time of Update: 2021-03-06
, of AstraZeneca, has been approved by the European Union to treat symptomatic heart failure with reduced blood test scores (HFrEF).
In , heart failure affects about 15 million people, at least half of whom have lower blood test scores.
-
The new drug, NaQuinate, has completed its first human trials
Time of Update: 2021-03-06
This combination of safety data from the first human study supports NaQuinate therapy to provide a safe, novel and intelligent treatment for bone diseases such as osteoporosis and to better safeguard the potential for healthy bone aging.
-
Peppa's Opdivo has won EU second-tier esophageal cancer approval
Time of Update: 2021-03-06
after testing positive ATTRACTION-3 in the third stage, EC approved Opdivo , a trial that looked at the comparison of PD-1 inhibitors with chemotherapy docetaxel or yew alcohol - as an irreversible treatment for patients with advanced or reoccessive esophageal squamous cell carcinoma (ESCC ).
-
Pfizer/BioNTech's COVID-19 vaccine is 90% effective
Time of Update: 2021-03-06
In today's announcement, Pfizer and BioNTech said their vaccines are more than 90 percent effective seven days after receiving a second dose.
The final analysis will also include a new secondary endpoint, i.e. an assessment of vaccine effectiveness based on cases generated after 14 days of the second dose.
-
AbbVie's leukemia drug Venclexta has been fully approved in the United States
Time of Update: 2021-03-06
This approval is significant because the data from our VIALE-A trial show that new diagnosed patients who cannot accept intensive chemotherapy can live longer than other patients after receiving VENCLEXTA gazazine treatment.
-
Suzhou Xinxu Pharmaceutical tau protein PET tracer clinical phase III trial was approved and started
Time of Update: 2021-03-06
Suzhou Xinxu Pharmaceuticals announced on the 22nd, the company's tau protein positive electron emission fault scanning (PET) tracer 18F-APN-1607 clinical phase III trial plan, has been approved by t
-
NICE supports AbbVie's Rinvoq treatment for rheumatoid arthritis
Time of Update: 2021-03-06
She added: "We are optimistic that we can also make positive claims decisions for those patients with serious illnesses who currently have limited treatment options." (cyy123.com) : NICE backs AbbVie's Rinvoq for severe active rheumatoid arthritis
-
Alnylam's third RNAi therapy lumasiran is about to be approved by the European Union
Time of Update: 2021-03-06
Alnylam recently announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review recommending the approval of the RNAi drug lumasiran for the treatment of primary high herbic acid uremia Type 1 (PH1).
-
Roche Tecentriq's joint Avastin therapy was approved in Europe
Time of Update: 2021-03-06
In addition, China's State Administration of Pharmaceutical Products has approved the combination therapy in October 2020 to treat non-removable HCC patients who have not previously received systematic treatment.
-
GSK's RSV vaccine candidate, Phase I/II, achieved positive results
Time of Update: 2021-03-06
candidate vaccine for respiratory syncytial cytovirus in GlaxoSmithKline has achieved some positive results in phase I/II studies.
-
Novaral Cosentyx first-line treatment
Time of Update: 2021-03-06
Novartis recently released data from two key international Phase 3 studies, which showed that Cosentyx (Chinese commodity names: good, common name: secukinumab, Skuchiyu monomatics, commonly known as "Sukin monomatics") provide rapid and powerful skin plaque removal and significantly improve quality of life in children and adolescents between the ages of 6 and 18.
-
FDA approves first drug to treat COVID-19
Time of Update: 2021-03-06
Hahn, "today's approval is supported by several clinical trial data rigorously evaluated by the FDA and represents an important scientific milestone in the COVID-19 pandemic." As part of the FDA Coronavirus Treatment Acceleration Program, we will continue to help transfer new medical products to patients as soon as possible, while determining whether they are effective and whether their benefits outweigh the risks.
-
AstraZenecom Fasenra Phase 3 Clinical
Time of Update: 2021-03-06
PONENTE is a multi-center, open-label, single-arm, IIIb phase trial conducted in patients with severe eosinophil asthma who receive high doses of inhaled corticosteroids (ICS), long-acting beta-2 astrations (LABA), long-term use of OCS therapy, co-use or unlinked with additional asthma control drugs, with the aim of assessing the effectiveness and safety of daily OCS use after initiating Fasenra 30mg subsurfacial injection (SC).
-
AstraZeneta's Tagrisso gets FDA priority review
Time of Update: 2021-03-06
AstraZenecon's Supplemental New Drug Application (SNDA) for Tagrisso is based on the results of the ADAURA Phase III trial, which showed that the disease-free survival rate (DFS) of the main analytical populations in phase II and IIa EGFR patients had statistically and clinically significant mutations in non-small cell lung cancer.
